Virological responses in chronic hepatitis C patients undergoing prolonged therapy with low-dose Peg-IFNα-2a.

BACKGROUND/AIMS: Standard dose therapy with pegylated interferon α-2a (Peg-IFNα-2a) and ribavirin is not suitable for all patients because of the side effects. This study aims to evaluate the virological responses of low-dose but long-course Peg-IFNα-2a therapy compared with standard therapy. METHODOLOGY: Ninety patients with chronic hepatitis C were divided into three groups according to their tolerance to Peg-IFNα-2a. The courses of treatment were 96 or 48 weeks respectively in patients with HCV genotypes 1b or 2a in the 67.5 µg and 90 µg groups, and were 48 or 24 weeks in the 180 µg groups. Serum HCV RNA was quantified to determine RVR, EVR, SVR and ETR. RESULTS: There were no statistical differences in HCV RNA load, HCV genotype at the baseline of the three groups (p>0.05). The rates of RVR, EVR, SVR and ETR (no significant differences in each group), were 63.04%, 82.61%, 71.74% and 85.87% in all 92 patients. Genotype 1b (95% CI=11.97-82.89; p=0.0075) and RVR (95% CI=0.12-0.53; p<0.001) were important predictors of SVR. CONCLUSIONS: Patients with low-dose but long-course Peg-IFNα-2a therapy had similar virological responses compared to those with standard therapy. HCV genotype and RVR were independent predictors of SVR.

Improved efficacy by individualized combination therapy with Peg IFN-a 2a and ADV in HBeAg positive chronic hepatitis B patients.

BACKGROUND/AIMS: Monotherapy with pegylated interferon alpha (Peg-IFNa) or adefovir dipivoxil (ADV) to HBeAg-positive chronic hepatitis B (CHB) patients has limited effects. This study aims to evaluate therapeutic efficacy and safety of individualized combination therapy with Peg-IFNa and ADV. METHODOLOGY: HBeAg-positive CHB patients (n=160) were enrolled in this multi-center, prospective, randomized, 'real-life' cohort study, of which received Peg IFNa-2a monotherapy or combination therapy with ADV base on the baseline features and treatment response. RESULTS: At week 24, percentages of ALT normalization, HBV DNA undetectable were both higher in individualized treatment group (ITG, 57.50%, 43.75%) than that in standard treatment group (STG, 40.00%, 27.50%; p=0.027, 0.032). The superiority of HBeAg clearance and seroconversion rates in ITG maintained from treatment termination (63.75%, 56.25%) to 48 weeks follow-up (57.50%, 53.75%). At week 96 the combined response rates were 46.25% in ITG compared with 30.00% in STG (p=0.034). Furthermore, there was no statistically significant difference in relapse rates and adverse events between the two groups. CONCLUSIONS: Individualized combination therapy can achieve higher antiviral response rates. In particular, it can accelerate undetectable HBV DNA and elevate HBeAg clearance/seroconversion rates to a greater degree than Peg-IFNa-2a monotherapy.

Association between Tooth Loss and Gastric Cancer: A Meta-Analysis of Observational Studies.

Observational studies showed that tooth loss is associated with gastric cancer, but the findings are inconsistent. In this study, a meta-analysis was conducted to evaluate the relationship between tooth loss and gastric cancer. Relevant studies were screened in PubMed and Embase databases, and nine observational studies were considered eligible for the analysis. The combined relative risks for the highest versus the lowest categories of tooth loss were 1.86 (95% CI: 1.08-3.21) and 1.31 (95% CI: 1.12-1.53) in case control and cohort studies, respectively. However, unstable results were observed in the stratified and sensitivity analysis. The current evidence, based solely on four case-control studies and five cohort studies, suggested that tooth loss is a potential marker of gastric cancer. However, we can not concluded at this time that tooth loss may be a risk factor for gastric cancer due to significant heterogeneity among studies and mixed results between case-control studies and cohort studies. Additional large-scale and high-quality prospective studies are required to evaluate the association between tooth loss and risk of gastric cancer.

[Application of nitrocellulose membrane in cell culture and pathological techniques].

OBJECTIVE: To provide a new supporting medium for carrying out cell culture and histological staining. METHOD: LoVo cell line was cultured using nitrocellulose membrane as the culture medium, in parallel with the same cell culture on the coverglass which served as control. RESULTS: The cells cultured on nitrocellulose membrane showed no visible difference from those cultured on coverglasses in terms of cell growth, morphology, and the structure displayed after staining. No toxic effect was observed due to the application of nitrocellulose membrane. CONCLUSIONS: Nitrocellulose membrane after treatment has such merit as good lucidity and stability without toxicity on the cells. Having also good affinity with the cells, nitrocellulose membrane can offer an promising alternative for glass as cell culture medium.

[Observation of special staining of human colorectal carcinoma cell lines cultured on nitrocellulose membrane].

OBJECTIVE: To observe the special staining of cells cultured on nitrocellulose (NC) membrane and evaluate the application of the novel method for cell culture and pathological staining. METHODS: Human colorectal carcinoma SW1116 cell line and SW480 cell line were cultured using nitrocellulose membrane as the culture matrix, with the same cells cultured on slides serving as the control. RESULTS: The cells cultured on NC membrane appeared transparent with sharp edge and purple background by macroscopic observation, showing on obvious difference in terms of cell morphology and number from the cells cultured on glass slides. Irregular polygonal SW1116 cells and SW480 cells were found on the NC membrane, on which the cells grew in colony and showed blue nucleus and red cytoplasm. CONCLUSIONS: NC membrane produces no cytotoxicity and can be used for cell culture without affecting the normal cell morphology and number during cell culture, thus providing a new means for cell culture and pathological staining.